CapSynth AI: A DeepTech platform providing a modular, enzyme-free chemical synthesis protocol for mRNA caps, integrated with an AI-driven process control system that optimizes reaction conditions in real-time to guarantee >95% purity and yield consistency, eliminating the single point of failure in mRNA supply chains.
Current mRNA vaccine production relies on enzymatic capping, which is a bottleneck causing 30-40% yield loss, high enzymatic degradation costs, and inconsistent batch quality. Biopharma companies face $50M+ per batch failure risk and 6-month delays in emergency deployment due to supply chain fragility for specific enzymes.